



Luxembourg, 01/12/2022

**Public**

## Environmental and Social Data Sheet<sup>1</sup>

### Overview

Project Name:	<i>ANOCCA (INVESTEU THEMATIC)</i>
Project Number:	<i>2022-0474</i>
Country:	<i>Sweden</i>
Project Description:	<i>Development of innovative next generation cell therapies targeting unmet medical needs in oncology indications</i>
EIA required:	no
Invest EU sustainability proofing required	yes
Project included in Carbon Footprint Exercise <sup>2</sup> :	no

### Environmental and Social Assessment

#### Environmental Assessment

Anocca is a Swedish biotechnology company with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity. The project supported by the EIB will target development of pre-clinical and clinical TCR-modified T-cell therapies (TCR-T) in oncology and investments allowing (Good Manufacturing Practices) GMP certification of Anocca's manufacturing plant.

The costs are mostly covering OPEX (e.g. personnel) and CAPEX (new and specialised equipment) to perform the high-end research and development activities.

The project concerns investments in research and development activities carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The research and development activities of the project do not fall under either Annex I or Annex II of the EU Directive 2014/52/EU amending 2011/92/EU.

The project is considered to be aligned with the Paris Agreement, as defined in the EIB Climate Bank Roadmap.

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

<sup>1</sup> The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

<sup>2</sup> Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO<sub>2</sub>e/year absolute (gross) or 20,000 tonnes CO<sub>2</sub>e/year relative (net) – both increases and savings.



Luxembourg, 01/12/2022

## **Other Environmental and Social Aspects**

If successful, the project will contribute to the creation and deployment of advances in the field of medicinal products targeting unmet medical needs in oncology indications by improving treatment options for patients and in turn the quality of life and productivity of patients.

Through the R&D activities and investments, the project will aid the Promoter to create additional highly skilled RDI jobs, while positively contributing to European scientific innovation, hence fostering and nurturing the vital research community.

The health and safety arrangements for the staff, especially those working with biological hazards, comply with the relevant EU directives and guidelines for workplaces, equipment, signs, personal protective equipment and exposure to biological agents at work according to the EU guidelines, and other relevant regulations.

## **Conclusions and Recommendations**

Sustainability proofing conclusion: the project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information and based on the review of the likely significant ECS risks and impacts and the mitigation measures and management systems in place, the project is deemed to have low residual ECS risks and impacts. No further sustainability proofing is required.

Considering the above, taking into consideration the Environmental, Social and Climate impacts of this RDI project, including the capacity of the promoter and the overall net positive social impact, this project is deemed acceptable for the Bank's financing under environmental and social terms.